Your browser doesn't support javascript.
loading
Do non-targeted gastric biopsies affect the management of patients, and can a simple protocol and education reduce the rate?
Gibson, Victoria; Needham, Stephanie; Nayer, Manu; Thompson, Nick P.
Afiliação
  • Gibson V; Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
  • Needham S; Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Nayer M; Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
  • Thompson NP; Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK.
Frontline Gastroenterol ; 9(1): 67-72, 2018 Jan.
Article em En | MEDLINE | ID: mdl-29484163
ABSTRACT

OBJECTIVE:

To determine whether development of localised protocol could reduce the number of non-targeted gastric biopsies taken at endoscopy, without risking harm from non-detection of malignant conditions.

DESIGN:

Retrospective analysis of patient records over a 3-month period in 2013, repeated in 2015 following intervention.

SETTING:

Two UK teaching hospitals. PATIENTS Patient record data on indication for endoscopy, endoscopy findings, histopathology results and patient outcome.

INTERVENTIONS:

Guidance on upper gastrointestinal biopsy in the form of a new trust-wide protocol, as well as lecture-based education. MAIN OUTCOME

MEASURES:

Rates of non-targeted and targeted biopsies before and after intervention, and differences between grade of endoscopist.

RESULTS:

Between 2013 and 2015, there was a 36% reduction in non-targeted biopsies (10.4% vs 6.7%, p=0.001), predominantly within registrar and nurse endoscopist groups, with reduction in non-targeted biopsies of 9.5% and 64%, respectively. Percentage of targeted biopsies remained relatively static, 7.9% and 8.2%. In 2013, 92% of non-targeted biopsies had no management change based on histology; in 2015 this was 90%. Of patients with alteration to management, only 0.4% and 0.7% were due to malignancy, in known high-risk patients. Reduction in non-targeted biopsies resulted in estimated annual savings in this trust of £36,000.

CONCLUSION:

Development of local protocol reduces the numbers of non-targeted biopsies taken, without risk of harm from non-detection of malignant conditions, enabling a significant reduction in workload within busy histopathology services, with significant cost savings. Localised protocols are adaptable to local population demographics.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article